HABIT-ILE: A Randomised Trial Of Hand Arm Bimanual Intensive Training Including Lower Extremity Training For Children With Bilateral Cerebral Palsy
Funder
National Health and Medical Research Council
Funding Amount
$1,100,903.00
Summary
In Australia, 35,000 people have cerebral palsy, and between 60-70% experience difficulties with movement on both sides of their body. There are currently no effective interventions for children with bilateral CP to improve their ability to use their hands, walk and perform daily life tasks. We have promising data about a new intervention, called HABIT-ILE, which we will test in 80 children with cerebral palsy and compare results to usual care.
Genetic selection of artificial polyketides. This project aims to harness the potential of synthetic biology to build cells that can make valuable new derivatives of polyketides. Polyketides are natural products that have proven to be highly effective for use in industry, medicine and agriculture. The technologies developed in this project will provide resources to discover new chemicals, accessible to almost any scientific laboratory. Expected outcomes include the opportunity to put the future ....Genetic selection of artificial polyketides. This project aims to harness the potential of synthetic biology to build cells that can make valuable new derivatives of polyketides. Polyketides are natural products that have proven to be highly effective for use in industry, medicine and agriculture. The technologies developed in this project will provide resources to discover new chemicals, accessible to almost any scientific laboratory. Expected outcomes include the opportunity to put the future of natural product discovery and optimisation in the hands of the wider scientific community, which will provide significant benefits, such as providing new tools for Australian industries.Read moreRead less
NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these ne ....NMR Studies of Second Generation Polynuclear Platinum Compounds. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students.Read moreRead less
DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the dr ....DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the drug to DNA and the subsequent reactions of the adducts formed. The results of this work will aid in the selection of back-up clinical candidates and in the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less
Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at t ....Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration betwe ....Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
NMR studies on DNA interactions of polynuclear platinum. BBR3464 is representative of a class of structurally unique platinum anticancer drugs, and is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow in detail the stepwise formation of DNA adducts. Further extension to reactions of polynuclear platinum complexes with sulfur ....NMR studies on DNA interactions of polynuclear platinum. BBR3464 is representative of a class of structurally unique platinum anticancer drugs, and is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow in detail the stepwise formation of DNA adducts. Further extension to reactions of polynuclear platinum complexes with sulfur nucleophiles will aid in understanding their metabolism and toxicity. The results of this work will aid in the selection of back-up clinical candidates and the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less
Gold phosphine and carbene complexes as potential antimitochondrial anticancer agents: design, synthesis and biological chemistry. To overcome the two major problems associated with existing anticancer drugs (resistance to therapy and lack of discrimination between normal and cancer cells) there is much current interest in targeting mitochondrial cell death pathways in chemotherapy. This project will probe the mode of action of a series of gold complexes containing pyridylphosphines that may ac ....Gold phosphine and carbene complexes as potential antimitochondrial anticancer agents: design, synthesis and biological chemistry. To overcome the two major problems associated with existing anticancer drugs (resistance to therapy and lack of discrimination between normal and cancer cells) there is much current interest in targeting mitochondrial cell death pathways in chemotherapy. This project will probe the mode of action of a series of gold complexes containing pyridylphosphines that may act by an antimitochondrial mechanism. Also, we will evaluate a new family of gold complexes based on carbene rather than phosphine components. Such compounds offer the potential advantages of ease of synthesis, lower toxicity and the ability to fine-tune molecular properties to maximise anticancer activity.Read moreRead less
Unleashing the Hidden Chemical Diversity in Australian Fungi. This project aims to exploit an exclusive genomic resource consisting of >150 unique Australian filamentous fungi that has been built in a university-industry collaboration for genomic-guided biodiscovery. The genome sequence of these fungi revealed extensive hidden genetic instructions for production of novel biologically active molecules. The project will apply cutting-edge synthetic biology and chemical tools to tap into the hidden ....Unleashing the Hidden Chemical Diversity in Australian Fungi. This project aims to exploit an exclusive genomic resource consisting of >150 unique Australian filamentous fungi that has been built in a university-industry collaboration for genomic-guided biodiscovery. The genome sequence of these fungi revealed extensive hidden genetic instructions for production of novel biologically active molecules. The project will apply cutting-edge synthetic biology and chemical tools to tap into the hidden genomic potential of these Australian fungi. Expected outcomes of this project include new fine chemicals and lead molecules with desirable bioactivies. This will provide significant benefits to Australia's economy through the discovery of new pharmaceuticals, veterinary products and agrichemicals.Read moreRead less
Fertility Management of Koalas, Kangaroos and Wallabies. The aims of this work are to test a commercially available long-acting contraceptive on large populations of kangaroos and koalas, and to devise efficient, economic and practical ways of delivering these contraceptives to the animals. The outcome will be a system of controlling the number of these animals which is economically realistic and acceptable to national and international communities. The contraceptive is administered as a small, ....Fertility Management of Koalas, Kangaroos and Wallabies. The aims of this work are to test a commercially available long-acting contraceptive on large populations of kangaroos and koalas, and to devise efficient, economic and practical ways of delivering these contraceptives to the animals. The outcome will be a system of controlling the number of these animals which is economically realistic and acceptable to national and international communities. The contraceptive is administered as a small, subcutaneous implant in the back of the neck. It can be inserted very quickly and has no harmful side effects. A further outcome may be its adoption in other parts of the world, to the advantage of the company which manufactures it.Read moreRead less